This is from http://ms.about.com/b/a/257703.htm
Chromos Molecular Systems—the developers of CHR-1103, a potential treatment for acute multiple sclerosis exacerbations—has announced that it will create an independent advisory board to guide the development of the medication and the application to the Federal Drug Administration (FDA) for approval to market the drug. CHR-1103 is a monoclonal antibody, which is intended to reduce the severity and length of relapses. The drug may also have the benefit of diminishing permanent damage caused by relapses. The announcement is a promising step toward bringing new treatments for multiple sclerosis to market.
Submitted 9/17/2006 1:03:43 PM